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Abstract
Background: Data from the Surveillance, Epidemiology, and End Results program and the European Concerted
Action on survival and Care of Cancer Patients (EUROCARE) project indicate that about 6% of women newly
diagnosed with breast cancer have stage IV disease, representing about 12 600 new cases per year in the United
States in 2005. Historically, local therapy of the primary tumor in this setting has been aimed solely at symptom
palliation. However, several studies suggest that surgical excision of the primary tumor can prolong these patients’
survival.
Discussion: Exclusive locoregional radiotherapy is an alternative form of locoregional treatment in this setting and
may represent an effective alternative to surgery in this setting. Here we discuss current issues regarding exclusive
and adjuvant locoregional radiotherapy in breast cancer patients with synchronous metastases.
Summary: Several studies suggest that surgery or exclusive irradiation of the primary tumor is associated with
better survival in breast cancer patients with synchronous metastases and that exclusive locoregional radiotherapy
may represent an effective alternative to surgery in this setting. Results of well-designed prospective studies are
needed to re-evaluate treatment of the primary breast tumor in patients with metastases at diagnosis, and to
identify those patients who are most likely to benefit.
Background
Data from the Surveillance, Epidemiology, and End
Results program and the European Concerted Action on
survival and Care of Cancer Patients (EUROCARE) pro-
ject indicate that about 6% of women newly diagnosed
with breast cancer have stage IV disease, representing
about 12 600 new cases per year in the United States in
2005 [1,2]. The 5-year overall survival rate among such
patients rarely exceeds 20% [3]. Survival can be improved
by endocrine therapy, chemotherapy, and biological ther-
apy [4,5]. Local treatment is often recommended to pre-
vent or relieve symptoms but is traditionally considered
to have no noteworthy impact on survival [4,5]. However,
several recent observational studies have shown that 35%
to 60% of breast cancer patients with stage IV disease at
diagnosis receive treatment for the primary tumor, con-
sisting mainly of surgery [6-19]. The results of these stu-
dies, coming from the SEER database, the National
Cancer Database (NCDB), the Geneva Tumor Registry
and several large comprehensive cancer center databases,
show that surgery of the primary tumor was associated in
most series with a relatively constant reduction in the
risk of death of about 40% [6-13,15-19] (table 1).
Locoregional treatment may also consist of exclusive
locoregional radiotherapy with the added advantage of
being a conservative treatment. Two recent studies have
evaluated the impact of locoregional radiotherapy direc-
ted to the breast and regional lymphatics among breast
cancer patients with synchronous metastases [14,20]. In
contrast, the role of postoperative radiotherapy in this
setting is poorly documented. The main objective of this
review is to highlight current issues regarding exclusive
and adjuvant locoregional radiotherapy in breast cancer
patients with synchronous metastases.
Discussion
Locoregional treatment in metastatic cancer and
pathophysiological hypotheses
Resection of the primary tumor has been linked to bet-
ter survival in several metastatic malignancies. Two
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cal treatment alone versus medical treatment plus
nephrectomy for metastatic renal carcinoma showed a
significant overall survival benefit among patients whose
primary tumor was removed [21,22]. Excision of the pri-
mary tumor is also known to be beneficial in stomach
cancer [23] melanoma [24] colon cancer [25,26], and
ovarian cancer [27]. Similarly, several recent observa-
tional studies have shown a survival advantage among
breast cancer patients with stage IV disease at diagnosis
whose primary tumor was completely excised [6-19].
The largest series was published by Khan et al., who
investigated the use and impact of local therapy among
16 023 breast cancer patients with synchronous
Table 1 Retrospective studies evaluating the treatment of the primary tumor in breast cancer patients with
synchronous metastases
Authors
(ref)
Database Years of
inclusion
Local
treatment
Number of
patients total/
local treatment/
no local
treatment
Characteristics associated with
a higher OS rate in
multivariate analysis
Multivariate Analysis of
Overall Survival Hazards
Ratio for Death (95%CI)
with local treatment
Kahn
et al. [13]
National cancer database
of the American college
of surgeons
1990-1993 S 16023/9162/6861 S, systemic therapy, number of
metastatic sites
HR OS (RO) = 0.61
(0.58-0.65)
HR (R1) = 0.751 (0.71-0.793)
Gnerlich
et al. [11]
SEER 1988-2003 S 9734/4578/5156 HR OS = 0.57 (0.55-0.60)
Bafford
et al. [7]
Dana Farber Cancer
Institute, Brigham and
Women’s Hospital and
Massachusetts General
Hospital
1998-2005 S 147/61/86 S, ER+, Her2+, no CNS metastasis HR OS = 0.47 (p = 0.003)
Shien
et al. [18]
National Cancer Center
Hospital
1962-2007 S 326/160/184 S, age <50, soft tissue or bone
metastasis
HR OS =
0.89 (0.79-1)
Blanchard
et al. [8]
Laboratory of the
university of texas health
science center
1973-1991 S 395/242/153 S, ER +, PR+, number of
metastatic sites
HR OS = 0.609
(0.489-0.757)
Fields
et al. [10]
Washington university
medical center
1996-2005 S 409/287/222 S, Bone only metastasis HR OS = 0.53 (0.42-0.67)
No difference in time to
metastatic progression
between the 2 groups
Babiera
et al. [6]
MD Anderson cancer
center
1997-2002 S 224/82/142 Only one site of metastasis, HER2
+, Caucasian ethnicity
HR OS = 0.5 (0.21-1.19)
HR TTFP = 0.54 (0.38-0.77,
p = 0.0007)
Hazard
et al. [12]
Lynn Sage Breast Center
(Northwestern memorial
Hospital)
1995-2005 S 111/47/64 NA HR OS = 0.798 (p = 0.52)
HR TTFP = 0.49 (p = 0.015)
Cady
et al. [9]
Massachusetts General
Hospital and Birgham and
Women’s Hospital
1970-2002 S 622/234/388 Young age, RH +, bone only
metastasis
Matched-pair analysis:
benefit of surgery
p < 0.0001
Ruiterkamp
et al. [17]
Eindhoven Cancer
Registry
1993-2004 S 728/288/440 Surgery, age, no more than one
metastatic site, no concomitant
disease(p = 0.06), systemic
therapy
HR OS = 0.62 (95%CI =
0.51-0.76)
Leung
et al. [19]
Medical College of
Virginia Campus of
Virginia Commonwealth
University,
1990-2000 S 157/52/105 Chemotherapy No benefit in multivariate
analysis
Rapiti
et al. [16]
Geneva cancer registry 1977-1996 S 300/127/173 Age < 60, none N3, ER+, none
visceral metastasis, none CNS
metastasis, hormonal treatment,
surgery with negative margins
HR OS = 0.6 if R0 (0.4-1.0)
NS if R1
Le Scodan
et al. [14]
René Huguenin Cancer
Center
1984-2004 RT 581/320/261 Only one metastatic site, young
age, LRT, no visceral metastases,
N0
HR OS = 0.7 (0.58-0.85)
S: surgery of the primary tumor, RT: radiation therapy, LRT: locoregional treatment, HR: hazard ratio, OS: overall survival, TTFP: time to first progression, 95%CI:
95% confidence interval, MST: median survival time, CNS: central nervous system, ER+: tumor positive estrogen receptor, PR+: tumor positive progesteron
receptor, Her2+: Her2 positive status, R0: surgery with negative margins, R1: surgery with positive margins, N0: clinical N0 lymph node status.
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of the American College of Surgeons between 1990 and
1993 [13]. Complete surgery of the primary tumor, i.e.
with free margins, was associated with a 39% reduction
in the risk of death: the 3-year survival rate was 35%,
compared to 26% and 17.3%, respectively, among
patients with positive margins and patients who did not
receive surgery (p < .0001). This survival benefit of
breast surgery persisted in multivariate analysis. Similar
conclusions were reached by Rapiti and coworkers:
among 300 women included in the Geneva Cancer Reg-
istry between 1977 and 1996, complete surgical resec-
tion of the primary tumor significantly improved overall
survival [16]. Analysis of the 1988-2003 SEER dataset
[11] and smaller series from other institutional data-
bases, such as the Baylor College [8] and MD Anderson
[6] also point to a benefit of surgery for stage IV breast
cancer (table1). Several mechanisms potentially support
the use of local treatment in the metastatic setting.
First, removal of the primary tumor may reduce the
total tumor burden, increasing the effectiveness of che-
motherapy, and limit an additional reseeding of tumor if
one considers that the primary tumor is the only contin-
uous source of metastases and that systemic spread
from metastatic lesions is less likely [28]. Total tumor
burden plays a central role in survival, since the number
of metastatic sites and the number of metastasis at a
given site is strongly correlated with survival of breast
cancer patients [29-32]. There is also a correlation
between the level of circulating tumor cells and the
prognosis of metastatic breast cancer [33,34]. Further-
more, it has been reported that chromosomal abormal-
ities in circulating tumor cells isolated from patients
with metastatic epithelial cancers match those in the
primary tumor, indicating that circulating cells are
derived from the primary tumor [28]. Second, removal
of the primary tumor may make metastases more che-
mosensitive, by inducing an angiogenic surge (thereby
increasing tumor vascularisation and drug penetration),
by removing necrotic tissue and non vascularised tumor
cells (which are classically less sensitive to chemotherapy
and radiation therapy) and by eliminating breast cancer
stem cells from the primary tumor, limiting the emer-
gence of chemoresistant cell lines [29-31,35]. Third,
removal of the primary helps to restore immunity and
to improve nutrional status. Indeed, some tumors,
including breast cancer, can induce an immunosuppres-
sive state and influence metastatic disease progression
possibly owing to cytokine secretion by tumor cells [35].
In a murine model, Danna et al. demonstrated that a
primary tumor may influence metastatic disease pro-
gression through the release of immunosuppressive fac-
tors and that removal of the primary tumor may result
in restoration of an immune response, even in the
presence of metastatic disease [36]. Fourth, surgery or
exclusive locoregional radiotherapy of the primary breast
tumor effectively prevents uncontrolled chest wall and
in-breast disease. Prospective randomized trials of post-
mastectomy radiotherapy have shown that local therapy
in the form of chest wall and lymph node irradiation
prolongs survival in node-positive non-metastatic
women receiving tamoxifen or chemotherapy [37-39].
This suggests that local therapy impacts survival in
breast cancer that is likely to be systemic and that
uncontrolled local disease may act as a source of tumor
reseeding, diminishing the effectiveness of systemic ther-
apy. This is supported by the finding that the increased
local recurrence rate after lumpectomy without radio-
therapy translates into poorer 15-year survival [40].
Moreover, a randomized controlled trial showed that
local recurence is predictive of distant dissemination
[41]. In the study by Hazard, surgery strongly protected
a g a i n s tu n c o n t r o l l e dc h e s tw a ll disease, suggesting that
the impact of local therapy on survival may be mediated
by better local control [12].
Thus, both mechanisms – a reduction in tumor bur-
den by removing the primary tumor that serves as the
source of tumor cell seeding, and better local control -
may be involved. Indeed, these mechanisms are linked,
because uncontrolled local disease may serve as a source
of systemic tumor reseeding. Opposite to the proposed
biological mechanisms in favor of treatment of the pri-
mary tumor, other theories have been proposed regard-
ing the effect of surgical removal of the primary tumor
on the growth kinetics of micrometastases. In contrast,
several authors suggested that surgical resection of the
primary breast tumor may accelerate relapse due either
to removal of inhibitors of angiogenesis and/or the
release of growth and immunosuppresive factors in
response to surgical wounding [42-45]. However, the lit-
erature review of the retrospective studies evaluating the
impact of surgical resection of the primary breast tumor
does not support this point of view.
Exclusive locoregional radiotherapy for the primary
breast tumor
Exclusive locoregional radiotherapy (LRR) is an alterna-
tive form of locoregional treatment (LRT) in this setting,
and has the advantage of breast conservation.
Several series support the use of LRR alone in the
management of breast c ancer and have shown good
locoregional control with local control rates of about
80% at 5 years [46-55]. For example, Dubray et al
reported local control rates of 86% and 74% at 5 and 10
years respectively, in 398 (33 T1, 309 T2, 56 T3) breast
cancer patients treated conservatively at Hôpital Henri
Mondor (France) by an initial course of external irradia-
tion (45 Gy, 25 fractions, 5 weeks) followed by
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the tumor [46]. We recently studied the impact of LRT,
consisting mainly of exclusive LRR, on the survival of
breast cancer patients with synchronous metastases trea-
ted between January 1984 and December 2004 at Rene
Huguenin Cancer Center, Saint Cloud, France [14].
Among 581 patients, 320 received LRT and 261 received
no LRT. LRT consisted of exclusive LRR in 249 cases
(78%), surgery of the primary tumor with adjuvant LRR
in 41 cases (13%), and surgery alone in 30 cases (9%).
Exclusive LRR delivered mean doses of 48.67 Gy
(range:5-50) and 48.01 Gy (range: 5-50), respectively, to
the affected breast and axillary and supraclavicular
lymph nodes. Eighteen patients received hypofractio-
nated LRR. One hundred fifty-eight patients (63.5%)
received an additional dose to the primary tumor (mean
dose: 22.95 Gy; range: 9-40; brachytherapy: 58 patients;
external irradiation: 100 patients). One hundred twenty-
four patients (42.7%) received an axillary boost (mean
dose 16.7 Gy, range: 9-25) and 57 patients (20%)
received a boost to the supraclavicular fossa (mean dose
11.17 Gy; range: 5-18). With a median follow-up of 39
months, the 3-year OS rates were 43.4% and 26.7%,
respectively, among patients who received or not LRT
(p = 0.00002). LRT was an independent factor of favour-
able outcome in multivariate analysis, taking into
account the main cancer-related prognostic factors
(hazard ratio, 0.70 [95%CI 0.58-0.85]; p = 0.0002). We
also evaluated the adjusted HR for the effect of LRT
from time 0 to 1 year and to 1 year or more. A similar
beneficial association between LRT and a lower risk of
death was observed, with an HR for death of 0.45 (95%
CI, 0.32 to 0.65; P < . 0 0 0 1 )f r o md i a g n o s i st o1y e a ra n d
an HR for death of 0.76 (95% CI, 0.61 to 0.96; P =. 0 2 )
1 year or more after diagnosis, suggesting that LRT
clearly impacts OS and that the effect of treatment is
not only a result of a treatment assignment bias.
Althought few patients were treated with surgery alone,
the median survival times and 3-year overall survival
rates were 26 months and 46% (95% CI, 29.60% to
63.60%) among the 30 patients treated with surgery
alone and 31 months and 41.5% (95% CI, 35.50% to
47.90%) among the 249 patients treated with exclusive
LRR, suggesting that exclusive locoregional radiotherapy
might be an effective treatment of the primary tumor.
Bourgier and colleagues from the Institut Gustave
Roussy, Villejuif, France, recently reported the outcome
of 239 breast cancer patients with synchronous metas-
tases who received locoregional treatment of the pri-
mary tumor [20]. Two-thirds of the patients had a sole
metastatic sites and 49% had non-visceral metastases at
diagnosis. They evaluated the effect of local treatments
(LRR alone: group 1; n = 147 versus surgery of the pri-
mary tumor with or without adjuvant radiotherapy:
group 2; n = 92) on local control, overall (OS) and
metastasis progression-free (MPFS) survival. Breast and
regional lymphatics were irradiated daily with hypofrac-
tionation (30 Gy/10 fractions; 63% of Group 1 patients)
or with conventional fractionation (50 GY/25 fractions;
32% of Group 2 patients) and a tumor boost was deliv-
ered to more than half of the patients. With a median
follow-up of 6.5 years, the 3-year MPFS rates were 20%
in group 1 and 39% in group 2; the 3-year OS rates
were 39% and 57% respectively. However, no significant
differences in MPFS or OS were observed between the
two groups when adjusted on known prognostic factors.
This study confirms that exclusive LRR is an effective
alternative to surgery in the management of breast can-
cer patients with synchronous metastases.
Role of adjuvant radiotherapy
In Kahn’s series, radiation therapy was received by 5806
of the 16 023 women, but no information was provided
on whether it was directed to the breast, the chest wall,
or osseous or symptomatic metastatic sites [13]; Rapiti
and colleagues reported that women who had surgery
(and especially breast-conserving surgery) were more
likely to have local radiotherapy too (21% vs 5%; P <
0.0001) [16]. Radiation therapy, delivered to 266 patients
(89%), was associated with significantly improved survival
in the multiadjusted model (hazard ratio for death with-
out radiation therapy, 1.6 (95%CI: 1.0-2.5)), but the
authors did not state whether irradiation was delivered to
the breast and regional lymphatics or to treat metastatic
sites. Gnerlich found that 41% of patients received radia-
tion therapy in the surgery group, compared to 34%
of patients in the no-surgery group, and that irradiation
was associated with a reduction in the risk of death in
univariate analysis (HR = 0.83, 95CI: 0.79-0.87), but it
was unclear whether or not irradiation was a prognostic
factor in multivariate analysis [11]. In the recent series
reported by Ruiterkamp and colleagues, locoregional
radiotherapy was not associated with better overall survi-
val in multivariate analysis [17]. In the study by Le Sco-
dan et al., the median survival times and 3-year OS rates
were 26 months and 46% (95% CI, 29.60% to 63.60%) for
the 30 patients treated with surgery alone, 31 months
and 41.5% (95% CI, 35.50% to 47.90%) for the 249
patients treated with exclusive locoregional radiotherapy,
and 39 months and 52.6% (95% CI, 37.60% to 67.20%) for
the 41 patients treated with s u r g e r yf o l l o w e db yl o c o r e -
gional radiotherapy, respectively (P = 0.07) [14]. How-
ever, comparisons between a multimodality treatment
targeting the primary tumor and regional lymphatics and
surgery alone must be undertaken with care, owing to
the potential selection bias. Thus, the possible benefit of
post-operative radiotherapy is unclear. Several rando-
mized trials have supported the use of hypofractionned
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in breast cancer patients with non-metastatic, node-nega-
tive disease [56,57]. If locoregional radiotherapy following
surgery of the primary tumor is considered to be of sig-
nificant interest in this metastatic setting, accelerated
radiotherapy may represent an active alternative to nor-
mofractionnated schedules.
Potential selection bias and ongoing phase III studies
The results of these recently published observationnal
studies raises two possibilities: either local treatment of
the primary provides a substantial survival benefit in
women with metastatic breastc a n c e ra td i a g n o s i s ,o r
there is a strong and consistent selection bias driving
the use of this treatment in women who have already
factors of better outcome. All retrospective studies are
likely to suffer from selection biases. Current clinical
decision-making seems to reliably identify women who
will do better, as most of the studies evaluating the
impact of the treatment of the primary breast tumor in
this context of metastatic disease showed an association
between surgery or exclusive radiotherapy and known
factors of good prognosis [6-19]. Indeed, women in the
surgical groups were younger, had smaller tumors and
fewer metastatic sites, and were more likely to have
bone/soft tissue metastases rather than visceral disease.
Finally, it is also possible that local treatment is a surro-
gate marker of more aggressive therapy overall, includ-
ing more aggressive systemic therapy, translating into
better survival. This possibility is supported by the fact
that, in several studies, patients were more likely to
receive radiotherapy [7,12,16,17] or chemotherapy
[6,14,17] when they had treatment of the primary
tumor. Thus, only a large prospective randomized trial
could settle this issue. Given the relatively minor
adverse effects associated with the treatment of the pri-
mary tumor, along with the relatively consistent survival
benefit observed in the different retrospective studies of
local surgery or radiation – and the estimated/12,000
breast cancer patients with synchronous metastases
diagnosed each year in the United States – a prospective
randomized trial is more than justified, although issues
of design, feasibility and priority of such a trial are more
complex. Such a study is under discussion among US
and European cooperative groups and two randomized
trials, one sponsored by the Turkish Federation of the
National Societies for Breast Diseases and the other by
Tata Memorial Hospital, India, are currently recruiting.
The Turkish trial is intended to enroll 271 patients in a
comparison of upfront surgery (mastectomy or breast
conserving surgery with level I-II axillary clearance in
clinically or sentinel lymph node positive patients) with
adjuvant therapies and systemic therapy only [58,59]. In
the systemic chemotherapy group, patients will only
receive surgery to control local complications.The
primary end-point is mortality and the secondary end
point is the assessment of quality of life within the
two groups. The estimated completion of this study is
October 2012. The Tata Memorial Hospital trial should
enroll 350 patients in a comparison of locoregional ther-
apy (i.e. surgery and adjuvant radiotherapy if indicated)
and no locoregional therapy, given after six cycles of
anthracycline-based chemotherapy [60]. Primary end-
points are time to progression and overall survival,
secondary are correlative science points such as change
in angiogenics factors. The estimated study completion
date is february 2011. In a preliminary report of this
trial (NCT00193778) (125 patients: 53 pts randomized
to surgery and 72 pts randomized to observation; med-
ian follow-up: 18 months), surgery of the primary tumor
was not associated with better PFS or OS [61]. However,
if positive, the results of these studies will be of interest
not only to women with initial stage IV disease but also
those with synchronous local and distant recurrences of
previously treated breast cancer.
Summary
Several studies suggest that surgery of the primary
tumor is associated with better survival in breast cancer
patients with synchronous metastases and that exclusive
locoregional radiotherapy may represent an effective
alternative to surgery in this setting. Results of well-
designed prospective studies are needed to re-evaluate
treatment of the primary breast tumor in patients with
metastases at diagnosis, and to identify those patients
who are most likely to benefit.
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